NCT07711444Completed
The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms
Eicosapentaenoic Acid and Specialized Pro-Resolving Mediator for Depressive Symptoms in Long COVID: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. Researchers planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan. The focus was on evaluating the therapeutic impact and potential side effects of administering 3 g/day of EPA or 1.67 mg/day of SPMs on symptoms of depression in these patients. This consolidated approach aims to provide comprehensive insights into the efficacy of EPA and SPM treatments in Long COVID cases, addressing crucial mental health aspects.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 54 (actual)
- First submitted
- 14 Jul 2026
- Start date
- 1 Jun 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- National Science and Technology Council, Taiwan
- Diseases
- Depression, Long COVID and ME/CFS
- NCT number
- NCT07711444
What you commit to
- Study type: Interventional
- Participants enrolled: 54
- From 1 Jun 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or past six-month diagnosis of psychotic disorder, bipolar disorder, substance use disorder, or other major psychiatric conditions based on ICD-10 or DSM-5 criteria
- Known allergy or intolerance to omega-3 fatty acids or SPMs; and
- Requirement for inpatient psychiatric care due to acute suicide risk
Lab values
- Significant neurological or medical comorbidities (eg, epilepsy, traumatic brain injury, autoimmune disease, cancer), acute infections, or clinically significant laboratory abnormalities
Other
- Regular use of SPM or EPA supplementation \>0·5 g/day
Who the study is looking for
- Confirmed SARS-CoV-2 infection by PCR, documented positive test, or clinician diagnosis
- Meeting CDC criteria for Post-COVID Conditions (Long COVID) as the presence of new, returning, or ongoing symptoms ≥4 weeks after confirmed SARS-CoV-2 infection
- Hamilton Depression Rating Scale (HAMD-21) score ≥18 at baseline
- Stable antidepressant treatment for ≥4 weeks or no current antidepressant use; and
- Ability to provide written informed consent
Age in the registry: 20 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mind-Body Interface Research Center (MBI Lab & Care) Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.